Stephen Gillies '75 BS is founder, president, and CEO of Provenance Biopharmaceuticals Corp., based in Carlisle, Massachusetts. Previously, he served as founding president of Fuji ImmunoPharmaceuticals, which later became EMD Lexigen Research Center and is now owned by Merck KGaA and known as EMD Serono. Gillies is an expert on recombinant antibodies and immunotherapy, and he has invented core platform technologies. During the course of his scientific career, Gillies has led multiple therapeutic candidates into clinical development for the treatment of cancer and HIV/AIDS. He earned his MS and PhD in microbiology from the Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey. He lives in Carlisle, MA.